Cannabis business operators and advisors have spent the last several years watching the market evolve from a THC-and-CBD story into something much more nuanced: the rise of the minor cannabinoid economy. As product categories mature and consumers become more sophisticated, demand is shifting toward non-intoxicating isolates and compounds that have specific therapeutic potential. This increased demand is creating a supply-chain bottleneck in the manufacturing vertical market segment.
I have been in the regulated cannabis industry for 22 years, and I have seen this industry sector change over that time. Not only have I operated cannabis businesses myself from 2005 to 2009, but I also currently provide tax and compliance services to over 100 license holders across 20+ states.
This industry shift is not a flash in the pan. It is the next stage of an evolving market sector that increasingly rewards functional outcomes, defensible IP and scalable production economics – most notably at the nexus of cultivation-to-manufacturing and its seemingly insurmountable bottleneck restricting minor cannabinoid supply.
The problem is that the plant itself is not built for industrial efficiency with respect to minor cannabinoids. Traditional cannabis and hemp cultivation remains a costly, resource-intensive process, and most cultivars express only a narrow slice of commercially useful compounds at meaningful levels.
Even in optimally-run operations, minor cannabinoids are typically present in trace amounts, and specific cannabis cultivars often yield only about 1% of minor cannabinoids as active compounds in the final harvested product.
For operators, that means large acreage requirements, specialized genetics programs, complex post-harvest processing and significant expenditures on water, energy, labor, extraction and compliance just to isolate very small volumes of target molecules.
The harsh reality is that scarcity creates a structural bottleneck for both commerce and science. Highly prized minor cannabinoids require massive scaling of cultivation and processing, and this economic factor makes production more expensive, less efficient and more environmentally burdensome.
The cultivation-to-processing bottleneck also slows down scientific research. When a compound cannot be produced consistently and at a commercial scale, it is difficult to study it rigorously, formulate it reliably or bring it through serious development pathways.
That observation gets to the core of where the industry is headed. The cannabis and hemp sector has historically been built around agriculture; however, the future of high-value cannabinoids production may appear more like biotechnology and precision manufacturing. Advisors and operators who understand that distinction early will strategically be better positioned than those still underwriting the category as a cultivation story alone.
This industry sector growth phase is where synthesis and production technologies become especially compelling. Companies such as eXoZymes, Inc. are advancing a model that uses enzymes, artificial intelligence and bioreactor-based manufacturing to produce non-intoxicating minor cannabinoids.
From an operations perspective, this is a meaningful departure from legacy cannabis and hemp production. Instead of planting more acres, investing in a controlled-environment agricultural facility, harvesting more biomass and extracting ever-smaller concentrations of target compounds, this disruptive model manufactures the valuable molecules directly, securing high purity through great precision and with far less waste, since no extraction or purification is needed.
The Rolling Stone Culture Council is an invitation-only community for Influencers, Innovators and Creatives. Do I qualify?
In practical terms, biomanufacturing can reduce dependency on volatile crop yields, seasonal constraints and the capital expenditures associated with large cultivation footprints. Minor cannabinoid synthesis can also create cleaner supply chains for formulators and product companies that need consistent inputs for wellness, pharmaceutical or functional consumer applications.
Just as important, synthetic manufacturing opens the door to compounds beyond the usual commercial shortlist. The industry has spent years focused on the best-known cannabinoids because those were the easiest to grow, extract and monetize, brute-forcing high yields.
Optimizing cannabinoid synthesis is the new frontier. But the most promising business opportunities may sit in rare or previously inaccessible molecules that traditional cultivation cannot produce at a meaningful scale. If those compounds can now be synthesized more efficiently, the total addressable market expands significantly.
Cultivating more biomass traditionally means processing at higher volumes, increased SKU complexity, additional labor, higher overhead costs and the waste of natural resources and utilities at every step of the chain.
The result: diminishing returns.
A technology platform that can directly produce target molecules has the potential to compress the process, reduce operational friction and improve planning reliability. In a sector that has often confused growth with asset heaviness, that is a major strategic advantage.
The implications are practical, and the returns are increasingly hard to ignore. Synthetic production is not just a scientific advancement; it is a shift in business models with several meaningful operational and financial benefits:
• Reduce the need to acquire large tracts of agricultural land, along with the associated costs, infrastructure and utility use
• Increase the production of therapeutic non-intoxicating cannabinoids that are otherwise difficult to access at scale
• Enable more consistent purity and batch-to-batch standardization, which is essential for clinical research, regulated consumer products and long-term brand credibility
• Improve capital efficiency by shifting value creation away from low-margin biomass and toward high-value, IP-driven ingredient production
When taken together, these advantages point to a future in which cannabis value is created less by acreage and biomass and more by precision, scalability and intellectual property.
The most prosperous will not simply be those who produce the most, but rather, those who can produce the right compounds, at the right quality, at the right scale and with the right cost profile. As a former operator and current advisor, I see manufacturing minor cannabinoids as the disruptive technology story worth paying attention to now. Creating a supply that will satisfy an ever-increasing demand for wellness products is what drives the evolution and innovation of cannabinoid manufacturing technology and the disruption of the status quo.
